Skip to main content
Premium Trial:

Request an Annual Quote

Beckman to Acquire Agencourt For Up to $140M; Plans New Personal Genomics Spin-Off

NEW YORK, April 27 (GenomeWeb News) - Beckman Coulter intends to purchase Agencourt Bioscience for up to $140 million in cash, the companies said today.

 

Beckman plans to acquire all of Agencourt's outstanding stock for $100 million in cash and make up to $40 million in contingent payments through 2007. Following the acquisition, which is expected to close near the end of May, Agencourt will become a wholly owned subsidiary of Beckman, and will remain based in Beverly, Mass.

 

Agencourt's management team and its workforce of about 100 will remain in place, according to the company.

 

In addition, Agencourt and Beckman plan a spin-off, to be called Agencourt Personal Genomics, which will develop a "sequencing by synthesis" approach for sequencing individuals' genomes.

 

Agencourt provides genome-sequencing services and a bead-based nucleic acid purification technology called SPRI. It is one of five large-scale sequencing centers funded by the National Human Genome Research Institute.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.